Serelaxin is a recombinant human relaxin-2 peptide being developed for the treatment of acute heart failure (AHF). The present analyses aimed to evaluate serelaxin pharmacokinetics following intravenous administration and to identify covariates that may explain pharmacokinetic variability in healthy subjects and patients.
Introduction
Serelaxin is a 6 kDa recombinant peptide that is identical in structure to human relaxin-2, which is a naturally occurring hormone that stimulates the vascular signalling pathways with reported short-and long-term effects on haemodynamics [1] [2] [3] [4] . Serelaxin is currently being developed for the treatment of acute heart failure (AHF) [5] [6] [7] [8] . In the phase III Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) study [6] , patients with AHF receiving serelaxin [a 48-h intravenous (i.v.) infusion of 30 μg kg -1 day -1 ] in addition to standard of care reported a significant improvement in dyspnoea, reductions in in-hospital worsening of heart failure (HF), and a 37% reduction in 180-day cardiovascular and all-cause mortality rates compared with patients receiving conventional therapy alone. Further confirmation on the reduction in mortality and worsening HF with serelaxin is currently being investigated in the second phase III study, RELAX-AHF 2 [8] .
In humans, serelaxin shows linear kinetics following i.v. administration [9] , and its serum concentration declines in a multiphasic manner [10] . Noncompartmental pharmacokinetic (PK) analyses in dedicated PK studies revealed that serelaxin PK was not affected by hepatic impairment [11] . Moreover, although a moderate decline in serelaxin clearance (CL) was observed in patients with severe renal impairment or end-stage renal disease (ESRD) compared with healthy subjects, the magnitude of this does not warrant any dose adjustment in these patient populations (mean peak plasma concentration: 15.6 ng ml -1 in healthy subjects and 21.5 ng ml -1 in ESRD patients) [12] . It was also found that serelaxin PK was similar in healthy Japanese and Caucasian subjects [9] . This pooled analysis of multiple phase I or phase II clinical studies was aimed at characterizing the PK of serelaxin in adults by conducting a population pharmacokinetic (PPK) analysis using compartmental modelling with a nonlinear mixed-effect approach, to identify the factors leading to variability in exposure across patients with AHF, chronic HF, hepatic impairment, renal impairment, compensated cirrhosis or portal hypertension, or in healthy subjects. In addition to the PPK analysis, a nonlinear quantile regression analysis of serelaxin CL was conducted to allow the inclusion of the sparse and more variable PK data from the phase III RELAX-AHF study.
Methods

Clinical trials
Serelaxin PPK analysis was performed using data from three phase I studies and six phase II studies, with the data from the phase III RELAX-AHF study added for the quantile regression analysis. The details of the studies included in PPK and quantile regression analysis are described in Table 1 . All clinical studies were approved by ethics committees and were reported in accordance with the ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Harmonized Tripartite Guidelines for Good Clinical Practice (ICHE6), applicable local regulations and the Declaration of Helsinki. All participants provided written informed consent before any study procedures were conducted.
All subjects received serelaxin as an i.v. infusion for different durations, ranging from 2 h in study X2201 up to 48 h in studies A2103, A2209, Pre-RELAX-AHF and RELAX-AHF.
PK assessments
Serial blood samples were collected for PK analysis before and at various time intervals following i.v. infusion of serelaxin (Table 1) . Serum serelaxin concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) based on the commercially available Quantikine ELISA kit DRL200 (R&D System, Inc. Minneapolis, MN, USA). The lower limit of quantification (LLOQ) was 15.6 pg ml -1 (calibration range 15.6-500 pg ml
) in most studies, except for the Pre-RELAX-AHF (phase II Relaxin for the Treatment of Acute Heart Failure) study, in which the LLOQ was 8 pg ml -1 (calibration range 8-500 pg ml -1 ). As the endogenous level of relaxin (which was measured at the predose baseline using the same ELISA method as for serelaxin) is in the pg ml -1 range (and, for most subjects, below the assay LLOQ), whereas the concentration of serelaxin during the infusion is in the ng ml -1 range, the impact of endogenous relaxin on the PK analysis of serelaxin is negligible.
PPK model development
The PPK analysis was conducted using a qualified installation of the nonlinear mixed-effect software Monolix version 4.3.2 (Lixoft, Antony, France). The R software version 3.2.3 was used to process the data and conduct graphical and statistical analysis [13] . The population analysis was conducted using a five-step approach for the selection of the structural model, and the covariates having a statistically and clinically significant impact on the PK profiles across patients. Owing to the use of bodyweight-based dosing in all the studies, the model parameters such as CL and the volume of distribution are also bodyweight normalized. Serelaxin concentrations that were below the LLOQ were handled by the Monolix algorithm, based on simulations of the left-censored data, using a righttruncated Gaussian distribution to estimate the likelihood that the value measured was lower than the LLOQ [14] .
Step 1 Serelaxin serum concentration-time data were compared between two-and three-compartment disposition models because a triexponential model was found to be the most appropriate for describing the PK of a single i.v. infusion of serelaxin. Intersubject variability in the PK parameters was modelled assuming log-normal parameter distribution, and the intrasubject variability was described using an additive-proportional error model.
Step 2 Following base model development, a total of 23 covariates of clinical interest were systematically evaluated on each compartmental model parameter, using a multivariate screening procedure for detecting the covariates with the highest explanatory power to describe the intersubject variability. The continuous covariates evaluated were age, bodyweight, body mass index (BMI), fat percentage, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) study equation [15] . The binary covariates were gender, race and an indicator variable for each study to detect differences across them (see Table S3 for covariate definitions).
The covariate screening procedure was based on the estimation of the correlation between samples of each individual posterior parameter distribution with each individual covariate value. The numerical correlation between each model parameter estimate and each covariate was quantified using a correlation-adjusted correlation (CAR) score [16] , which allowed the ranking of the importance of each covariate considering the correlation between covariates (see Section 1.1 in Supporting Information).
Step 3 A backward elimination (BE) procedure was performed using the preselected covariates in Step 2 to obtain the model with the smallest number of covariates and maximum explanatory power according to the Bayesian information criterion (BIC; see Section 1.2 in the Supporting Information for further description). The covariate model was implemented as the power-law model, as described in Section 1.3 in the Supporting Information and Table S3 .
Step 4 The clinical impact of the covariate selected by BE was then assessed by simulation of the PK profiles of a typical subject (a subject with a BMI of 29.8 kg m -2 , an eGFR of 59 ml min -1 1.73m -2 , and without HF), with or without the effect of the covariates. Covariates that did not change PK profiles markedly, particularly the concentrations at 48 h post-infusion, were discarded.
Step 5 Finally, a second BE step was performed using
Monolix and the BIC criteria described in the Step 3 to confirm that the covariate model selected in Step 4 provided the best compromise between explanatory power and simplicity.
Model evaluation
Standard goodness-of-fit plots (e.g. observed vs. predicted data plots, weighted residual was plotted against populationpredicted values, weighted residual was plotted against time) and visual predictive checks were used for model evaluation. For visual predictive checks, 500 simulated replicates of the dataset were simulated with Monolix, and the model was considered adequate if the observed concentration data were distributed within the 90% prediction interval of the simulated data.
Quantile regression analysis
The high variability in concentrations observed in the phase III RELAX-AHF study and measurement of only one serelaxin concentration per patient in this study (at 24 h post-infusion) suggested that a population approach, including the sparse data from the latter study, was not appropriate. Therefore, a nonlinear quantile regression analysis of CL as a function of the covariates selected in the PPK was conducted by pooling the CL estimated for each individual in the PPK and that estimated directly from the concentration measured in each patient in RELAX-AHF.
Patients with a stable infusion rate were included in the analysis. Using the dosing rate (normalized by bodyweight at baseline) and steady-state concentration, the bodyweightnormalized elimination CL at the time of PK measurement was estimated as follows:
Rate μg kg -1 day
Css ng ml
where Rate is the dosing rate used in each patient, Css is the steady-state concentration closest to the end of infusion, Weight baseline is the weight at baseline used to normalize the dosing rate and Weight PK measurement time is the bodyweight measured at the time closest to the measurement of the serelaxin concentration. For the other studies included in the PPK analysis, the CL estimate for each individual was given by the empirical Bayes estimate (EBE) obtained from the PPK analysis.
A quantile regression approach was preferred to a more standard ordinary least-square (OLS) regression approach (see Section 1.5 in the Supporting Information) to analyse these data because the former approach is less sensitive to outlier concentrations [17] . The quantile regression analyses were performed using the package quantreg 5.21 [18] in the R environment version 3.2.3 [13] . 
Total bilirubin (mg dl Other 6 (0.6) n = 1015 is the total number of subjects that produced this summary statistics ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [19] .
Results
Subject characteristics and raw data
Data from 1015 adults, including 66.3% men and 33.7% women, contributing 6799 serum serelaxin concentration measurements, were included in the quantile regression analysis; 157 of these concentrations were lower than the LLOQ. For the PPK analysis, 613 of the 1015 subjects were included. The characteristics of the population are summarized in Table 2 . Overall, the study population was mostly Caucasian (91.8%), the mean age was 67 years, and 493 (48.6%) subjects had moderate-to-severe renal impairment. The PK parameters obtained using a noncompartmental analysis and extracted from the clinical study reports of each study are presented in Table . Individual serelaxin concentration-time data for each study are presented in Figure 1 . The serelaxin concentration-time profiles showed at least a biphasic decline, indicating that a two-compartment disposition model would be a good starting point for the PPK analysis.
Outliers were removed from the PPK dataset, based on the exclusion criteria specified in the individual studies. In addition, for study A2209, concentrations >80 ng ml -1 , constituting <3% of the concentrations available in that study, were considered as outliers (because they are approximately >5 times the median concentration observed with a nominal dose rate of 30 μg kg -1 day -1 ) and were removed from the PPK dataset.
Figure 1
Pharmacokinetic serum concentration-time profiles of intravenously administered serelaxin in each study. Pre-RELAX-AHF, phase II Relaxin for the Treatment of Acute Heart Failure; RELAX-AHF, phase III Relaxin for the Treatment of Acute Heart Failure PK base model
The base model obtained after Step 1 of model development was a linear three-compartment disposition model defined in terms of CL, the central volume of distribution (Vc), the volume of the peripheral compartments (Vp2 and Vp3), and intercompartmental CL (Q2 and Q3; see Table S2 for model parameter estimates). Estimates of intersubject variability for all parameters ranged from 23% to 74%, whereas the intrasubject variability (%CV) was estimated to be 24%. No nondiagonal covariance term between model parameters was included owing to the absence of significant parameter correlations obtained from the individual posterior samples ( Figure S2 ) compared with the parameter correlations obtained from the EBEs showing a stronger correlation ( Figure S3 ). This reflects the shrinkage effect on the EBEs rather than the true correlation pattern between parameters [20, 21] .
Covariate search
In Step 2 of model building and for each model parameter, the CAR scores describing the correlations between the model parameter estimates (obtained from the posterior samples from each individual, using the PK base model without covariates) and all the covariates were estimated. Covariates were ranked using the squared CAR score (see Table S4 , where CL is used as an example). The optimal number of covariates (i.e. the minimum number of covariates which maximizes the explained variance) to be selected from this ranked list of covariates was estimated by visual inspection of the coefficient of determination, R 2 , and its uncertainty obtained from bootstrap resampling (e.g. see Figure S4 , where CL is used as an example) and the mean square error obtained by cross-validation (see Figure S5 , where CL is used as an example). The covariates selected for each parameter with this CAR score approach, and to be used in the next step (BE) of the model building process, are shown in Table 3 .
BE was performed in two steps, to reduce the computation burden, by performing the elimination on the covariates for CL and Vc first and then on the covariates for Vp2, Vp3, Q2 and Q3 ( Figure S6 ). The variables selected by BE are shown in Figure S7 .
The clinical significance of each covariate was then assessed by simulation of the typical subject PK profile, with or without the effect of the covariate (e.g. Figures S7, S8 and S9). If a covariate was selected for several model parameters (e.g. age on Vp2 and Vp3), the impact of the covariate was simulated successively, as if the covariate had an effect on only one parameter, then on all combinations involving the covariate on two parameters, and so on until the effects of the covariate on all the parameters selected by BE were included (e.g. see Figure S10 ).
From these simulations, some covariates were removed from the model because they did not make any changes to the PK profile (in particular, the concentrations at 48 h post-infusion) that would be deemed clinically significant or relevant by comparison with the PK profiles without any covariate effect.
Based on this selection of covariates, a final BE procedure was performed to ensure that no model with a smaller number of covariates offered a better compromise between model accuracy and model simplicity.
Final model
The parameter estimates for the final model are shown in Table 4 . Goodness-of-fit plots for this final model showed an adequate fit of the model, with no appreciable systematic trends (see Figures 2 and 3 , and Figure S11 ). The visual predictive check indicated an overall satisfactory distribution of the observed data in the prediction intervals (Figure 4) . The estimated population bodyweight-normalized CL was 83.3 ml /h -1 kg -1 , with an intersubject variability of 41%.
The covariates on CL identified were BMI and eGFR at baseline, and the categorical covariate indicating that a patient was part of study A1201 (study identifier) in Japanese patients with AHF as described in the following equation: The continuous covariates, BMI and eGFR, showed a moderate effect on CL because the covariate distribution results in a parameter distribution close to the 75-125% range vs. a typical subject ( Figure 5) . Similarly, the categorical covariate, indicating that a patient belonged to study A1201, had a moderate effect, with a 27% reduction in CL vs. a typical subject ( Figure 5 ). Furthermore, these covariates account for only a small portion of the intersubject variability in CL, which decreased from 44% in the base model to 41% in the final model with covariates.
The estimated values for Vc, Vp2 and Vp3 were 93.0 ml h -1 kg -1 , 165.2 ml h -1 kg -1 and 88.6 ml h -1 kg -1 , respectively, with an intersubject variability of 72%, 42% and 27%, respectively. The covariates identified by BE were the indicator function for patients belonging to study Table 3 Covariates selected by correlation-adjusted correlation (CAR) score and included in backward elimination in the population pharmacokinetic analysis Population pharmacokinetics of serelaxin A2201 on Vc and Vp2, and the indicator function for study A2202 on Vp2. Therefore, compared with subjects without HF, Vc and Vp2 are 1.6-and 1.9-fold higher, respectively, in Caucasian patients with AHF in study A2201, whereas Vp2 is 1.5-fold higher for Caucasian patients with chronic HF in study A2202. Using the final model with covariates, the impact of the selected covariates on the typical subject profile is shown in Figure 6 for the categorical covariates, and in Figure 7 for the continuous covariates. As previously mentioned, the CL is lower in patients in study A1201, which translates into a higher concentration in the typical subject in this study, as seen in Figure 6 . The volumes of distribution are higher in patients with HF in the A2201 and A2202 studies, which implies a longer time to reach steady state compared with that observed in patients without HF (as the CL was the same for a typical patient in studies A2201 and A2202). However, the maximum concentration reached is similar to that in patients without AHF because CL is no different between patients with and without HF (except for study A1201 in Japanese patients with AHF). The continuous covariates, BMI and eGFR, have an impact on CL and thus on the steady-state concentration. For example, patients having a BMI at its 95th percentile (40.1 kg m -2 ) or an eGFR close to its 5th percentile (28.5 ml min -1 1.73 m -2 ) in the pooled dataset have a steady-state concentration close to 21 ng ml, whereas a typical subject having a BMI or an eGFR at the median of the population distribution has a steady-state concentration close to 17 ng ml -1 . • t_BMI0 = log (BMI0/29.8)
• t_EGFR0 = log (EGFR0/59)
Quantile regression analysis
A quantile regression analysis was performed on CL, using the continuous covariates selected in the PPK analysis with the addition of the phase III RELAX-AHF data. Figure 8 depicts the scatter plot of bodyweightnormalized CL as a function of BMI and eGFR, as well as the curve fitting of CL as a function of BMI and eGFR, with a quantile regression power-law model in blue and the power-law model obtained with the PPK parameters in orange. The quantile regression was performed on the median (solid line) and on the 25th and 75th quartiles (dotted lines). The upper limit on the y-axis was set to 200 ml h -1 kg -1 but the quantile regression was based on the full dataset without removal of any values beyond the outliers described in the methods. A sensitivity analysis ( Figure 9 ) was conducted to assess the correlation between CL and eGFR when different sets of studies were included in the quantile regression analysis. In all the analyses, eGFR and BMI at baseline were included as covariates in the quantile regression analysis, to match the covariates on CL selected by the PPK approach. All the regression lines are very close to each other and show a weaker 
Discussion
The aims of these analyses were to describe serelaxin PK and to determine the impact of covariates on the observed PK variability. Serelaxin PK were modelled using a threecompartment disposition model, with linear elimination that adequately described individual concentration-time data.
A large intersubject variability was observed for Vc (72%), but no covariate was identified to reduce this variability substantially.
The impact of demographic covariates, kidney and liver function markers, and study effects on the PK model parameters, including CL and the volumes of distribution, were systematically investigated using a combination of multivariate regression based on CAR scores and a BE procedure using a nonlinear mixed-effect approach (a more thorough discussion of the methodology benefits used in the present analysis is given in Section 1.4 of the Supporting Information).
The covariates identified for CL were BMI and eGFR at baseline, as well as the categorical covariate, indicating that a patient belonged to study A1201.
The bodyweight-normalized CL of serelaxin increases with an increase in eGFR, indicating partial elimination of serelaxin by the kidney. The CL decreases with higher BMI but this effect is difficult to interpret because the CL is bodyweight normalized. Without bodyweight normalization, the dependency of CL (expressed in ml h -1 ) as a function of the bodyweight at baseline WT0 and height HT0 indicates increasing CL with higher BMI, as one would expect. These continuous covariates have only a moderate effect on the model parameters as, when the covariate values were set at the 5th or 95th percentile values, the model parameters were close to the 75-125% interval of the typical subject value. The reason for the CL being 27% lower in study A1201, which was conducted in Japanese patients with AHF, Figure 4 Visual predictive check for the final population pharmacokinetic model: predicted vs. observed (OBS) pharmacokinetic profiles. Observed concentrations are present on a linear scale, with empirical percentiles obtained from the data and 95% confidence intervals around the median and the 10% and 90% percentiles as theoretically predicted by the model is unknown. In fact, none of the study indicator covariates for study A2103 in Japanese subjects without AHF or for study A2201 in non-Asian patients with AHF were identified as significant covariates, and hence were not included in the final covariate model on CL. This suggests that the lower CL observed in study A1201 was unlikely to have been due to race or AHF alone, as patients with or without AHF, either Asian or not, had a CL that was statistically different from the population estimate. Moreover, categorical covariates had an impact on Vss (Vss = Vc + Vp2 + Vp3), with an increase in Vss from 347 ml kg -1 for a typical subject to 544 ml kg -1 for patients with AHF in study A2201 and 434 ml kg -1 for patients with chronic HF in study A2202. These elements are consistent with the hypothesis that patients with HF have a higher extracellular fluid volume [22, 23] . In fact, given that the extracellular volume of water and total body water volume are approximately 200 ml kg -1 (equivalent to 20% of human bodyweight) and 600 ml kg -1 (equivalent to 60% of human bodyweight), respectively [24] , it is likely that the Vss of serelaxin (which is a hydrophilic peptide) will be sensitive to changes in the fluid volume. Therefore, the differences in the steady-state volume (Vss) in healthy subjects and in patients with HF may reflect the differences in fluid retention between these two populations. Meanwhile, we also recognize that the indicator functions for studies A1201, A2209 and Pre-RELAX-AHF in AHF patients were not included as covariates on any volumes of distribution, which appears to contradict the fact that the volumes of distribution are higher in patients with HF. However, the PK sampling in these studies was so sparse (6, 12, 24 and 48 h for A1201; 8, 24 and 48 h for A2209; and 12 h for Pre-RELAX-AHF) that they would not have allowed a change in the time to reach steady state, induced by a change in the volumes of distribution, to be captured reliably.
Another limitation of the modelling approach taken to estimate the total Vss was the assumption regarding the mechanism of drug CL, which was assumed to take place from the central compartment. This could be questioned, as serelaxin elimination is partly due to catabolism and may take place in the peripheral compartments. The model would be unidentifiable if CL from peripheral compartments The white circles represent the continuous covariate values with 95% confidence intervals (CIs) when the covariate is set at its 5th or 95th percentile value, and the red circles represent the categorical values with 95% CIs. BMI0, body mass index at baseline; CL, clearance; eGFR0, estimated glomerular filtration rates at baseline 2 and 3 were also included; therefore, we restricted it to the central compartment. However, it was previously reported that when multiple CL processes occur in several compartments, it is only possible to estimate a range of values for the total volume of distribution at steady state (Vss), rather than a single value [10, 25] . The impact of the covariates eGFR and BMI at baseline on CL as observed using the PPK approach was also investigated,
Figure 6
Typical simulated subject profiles based on population pharmacokinetic parameter estimates with or without taking into account a single categorical covariate effect Figure 7 Typical simulated subject profiles based on population pharmacokinetic parameter estimates with or without taking into account a single continuous covariate effect, using the 5th and 95th percentile values of the covariate. BMI0, body mass index at baseline; eGFR0, estimated glomerular filtration rate at baseline Figure 8 Predictions of clearance as a function of baseline BMI or eGFR using the quantile power law model vs. the power law model from the population pharmacokinetics analysis. BMI0, body mass index at baseline; eGFR0, estimated glomerular filtration rate at baseline Figure 9 Quantile regression sensitivity analysis with a power-law model, including eGFR and BMI at baseline as covariates. The pooled analysis, which included all the studies (black curve), is compared with the regression on the median of A2102 alone (red curve). Different pooled datasets are described in the key. BMI, body mass index; eGFR, estimated glomerular filtration rate Population pharmacokinetics of serelaxin through a quantile regression analysis that included the phase III study (RELAX-AHF), in addition to the studies included in the PPK analysis. The power-law model on CL obtained through quantile regression compared with that used in the PPK approach showed similar trends for the change in CL as a function of BMI and eGFR. However, the CL estimated using the PPK approach was consistently lower than that estimated by the quantile regression analysis, reflecting the fact that the CL in the phase III trial seems to be higher than that observed in the PPK dataset. Furthermore, the correlation between serelaxin CL and eGFR was reduced in the pooled quantile regression analysis vs. that observed based on data from the A2102 study alone (Figure 9 ). The extreme eGFR values in patients with severe renal impairment or ESRD and in healthy subjects in the latter study possibly caused a stronger correlation vs. the pooled analysis. Overall, the impact of eGFR and BMI on CL according to the quantile regression analysis remains moderate because with this model a 20% increase in the median BMI would translate into a relative change of À9.2% in the bodyweight-normalized serelaxin CL, whereas a 20% decrease in eGFR would correspond to a decrease of 5.2% in CL. These changes are not considered clinically significant owing to the interpatient variability of 41% observed for CL, and no dose adjustment in patients with renal impairment is warranted. Similarly, as there is no significant impact of ALT, AST or total bilirubin on CL or any other model parameters, dose adjustment is not required in patients with hepatic impairment, which is consistent with the previous conclusion based on the noncompartmental PK analysis in study A2101 [9] .
In summary, a PPK analysis using a nonlinear mixed-effect approach, and also a nonlinear quantile regression analysis were conducted on pooled data from a large number of serelaxin clinical studies across a variety of subject populations. These analyses successfully characterized the PK of serelaxin following i.v. administration and provided an understanding of the various factors contributing to the interindividual PK variability. The analyses identified statistically significant covariates having an impact on serelaxin PK and helped to put them into the context of clinical implications by quantifying the extent of these changes. In addition, the analyses helped to rule out covariates that did not affect serelaxin PK and provided further support for the conclusions reached in individual dedicated clinical studies in special patient populations.
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